Restoration of Epithelial Sodium Channel Function by Synthetic Peptides in Pseudohypoaldosteronism Type 1B Mutants by Anita Willam et al.
ORIGINAL RESEARCH
published: 24 February 2017
doi: 10.3389/fphar.2017.00085
Frontiers in Pharmacology | www.frontiersin.org 1 February 2017 | Volume 8 | Article 85
Edited by:
Gildas Loussouarn,
University of Nantes, France
Reviewed by:
Stephan Kellenberger,
University of Lausanne, Switzerland
Yoshinori Marunaka,
Kyoto Prefectural University of
Medicine, Japan
*Correspondence:
Anita Willam
anita.willam@univie.ac.at
Specialty section:
This article was submitted to
Pharmacology of Ion Channels and
Channelopathies,
a section of the journal
Frontiers in Pharmacology
Received: 08 November 2016
Accepted: 09 February 2017
Published: 24 February 2017
Citation:
Willam A, Aufy M, Tzotzos S,
Evanzin H, Chytracek S, Geppert S,
Fischer B, Fischer H, Pietschmann H,
Czikora I, Lucas R,
Lemmens-Gruber R and Shabbir W
(2017) Restoration of Epithelial
Sodium Channel Function by
Synthetic Peptides in
Pseudohypoaldosteronism Type 1B
Mutants. Front. Pharmacol. 8:85.
doi: 10.3389/fphar.2017.00085
Restoration of Epithelial Sodium
Channel Function by Synthetic
Peptides in
Pseudohypoaldosteronism Type 1B
Mutants
Anita Willam 1*, Mohammed Aufy 1, Susan Tzotzos 2, Heinrich Evanzin 1, Sabine Chytracek 1,
Sabrina Geppert 1, Bernhard Fischer 2, Hendrik Fischer 2, Helmut Pietschmann 2,
Istvan Czikora 3, Rudolf Lucas 3, Rosa Lemmens-Gruber 1 and Waheed Shabbir 1, 2
1Department of Pharmacology and Toxicology, University of Vienna, Vienna, Austria, 2 APEPTICO GmbH, Vienna, Austria,
3 Vascular Biology Center, Medical College of Georgia, Augusta University, Augusta, GA, USA
The synthetically produced cyclic peptides solnatide (a.k.a. TIP or AP301) and its
congener AP318, whose molecular structures mimic the lectin-like domain of human
tumor necrosis factor (TNF), have been shown to activate the epithelial sodium
channel (ENaC) in various cell- and animal-based studies. Loss-of-ENaC-function
leads to a rare, life-threatening, salt-wasting syndrome, pseudohypoaldosteronism type
1B (PHA1B), which presents with failure to thrive, dehydration, low blood pressure,
anorexia and vomiting; hyperkalemia, hyponatremia and metabolic acidosis suggest
hypoaldosteronism, but plasma aldosterone and renin activity are high. The aim of
the present study was to investigate whether the ENaC-activating effect of solnatide
and AP318 could rescue loss-of-function phenotype of ENaC carrying mutations at
conserved amino acid positions observed to cause PHA1B. The macroscopic Na+
current of all investigated mutants was decreased compared to wild type ENaC when
measured in whole-cell patch clamp experiments, and a great variation in the membrane
abundance of different mutant ENaCs was observed with Western blotting experiments.
However, whatever mechanism leads to loss-of-function of the studied ENaC mutations,
the synthetic peptides solnatide and AP318 could restore ENaC function up to or even
higher than current levels of wild type ENaC. As therapy of PHA1B is only symptomatic
so far, the peptides solnatide and AP318, which directly target ENaC, are promising
candidates for the treatment of the channelopathy-caused disease PHA1B.
Keywords: pseudohypoaldosteronism type 1B (PHA1B), amiloride-sensitive epithelial sodium channel (ENaC),
lectin-like domain of tumor necrosis factor (TNF), TIP peptides, solnatide (AP301), AP318
Abbreviations: ASIC1, acid-sensing ion channel subunit 1; CRDs, cysteine-rich domains; ENaC, epithelial sodium
channel; ENaC/DEG, ENaC/degenerin family; HEK-293, human embryonic kidney; PHA1B, pseudohypoaldosteronism type
1B; PNGase F, peptide-N4-(N-acetyl-β-D-glucosaminyl)asparagine amidase F; peptide N-glycanase; SGK-1, serum- and
glucocorticoid-regulated kinase 1; TM, transmembrane; TNF, tumor necrosis factor; WT, wild type.
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INTRODUCTION
The amiloride-sensitive epithelial sodium channel (ENaC),
a member of the ENaC/degenerin (ENaC/DEG) family
of ion channels (Canessa et al., 1993; Lingueglia et al.,
1993; Kellenberger and Schild, 2015), is responsible for the
maintenance of Na+ balance, extracellular fluid volume and
blood pressure (Garty and Palmer, 1997). ENaC is located
at the apical membrane of salt-reabsorbing tight epithelia of
the distal nephron, the distal colon, salivary and sweat glands
and the lung, where it constitutes the rate-limiting step for
vectorial movement of Na+ ions from the luminal side into
the cell interior; the basolaterally located Na,K-ATPase actively
transports Na+ out of the cell, providing the driving force for
Na+ reabsorption (Kellenberger and Schild, 2002). In the kidney
and the colon, Na+ reabsorption through ENaC, stimulated by
the mineralocorticoid hormone aldosterone, is crucial for the
maintenance of blood Na+ and K+ levels and their homeostasis
(Kellenberger and Schild, 2002). In the lung, Na+ transport
through apically-located ENaC in the alveolar epithelium is
crucial for maintaining the correct composition and volume of
alveolar lining fluid, enabling optimal gas exchange (Matalon
et al., 2002).
The number of channels in the apical membrane depends
on a balance between the rates of ENaC insertion into and
removal from the membrane (Malik et al., 2006). In the distal
nephron and collecting tubules of the kidney, aldosterone
increases the number of active ENaC channels at the cell
surface via two pathways: induction of de novo synthesis of
ENaC subunits and reduction of ENaC retrieval from the
membrane and degradation. Binding of aldosterone to the
mineralocorticoid receptor results in formation of a complex
which migrates to the nucleus and induces transcription of
ENaC subunit genes. Aldosterone has a more immediate effect
on ENaC membrane abundance through induction of the
serum- and glucocorticoid-regulated kinase 1 (SGK-1), which
phosphorylates the E3 ubiquitin ligase, Nedd4-2, preventing
its binding to consensus proline-rich PPxY motifs in the
carboxyl terminal domain of ENaC subunits, thus disrupting
channel ubiquitination and subsequent internalization (Snyder,
2005; Butterworth et al., 2009). Evidence also exists for
Nedd4-2-mediated regulation of ENaC membrane abundance
in lung epithelia (Boase et al., 2011; Gille et al., 2014; Han
and Mallampalli, 2015). In the colon, ENaC-mediated Na+
absorption from the intestinal lumen is under glucocorticoid
control (Schild, 2010).
Four types of homologous subunit have been observed
to constitute ENaC: α, β, γ, and δ (Canessa et al., 1994;
Waldmann et al., 1995). A functional, pore-forming channel
usually comprises one or two α- or δ-subunits, together with a β-
and a γ-subunit (Canessa et al., 1994; McNicholas and Canessa,
1997). Following the determination of the trimeric structure of
the ENaC homolog ASIC1 (Jasti et al., 2007), it has been widely
accepted that ENaC forms a heterotrimer, although evidence for
tetrameric as well as trimeric assemblies exists (Firsov et al., 1998;
Kosari et al., 1998; Snyder et al., 1998; Anantharam and Palmer,
2007; Stewart et al., 2011).
Each subunit has a large extracellular loop separating two
transmembrane domains with short cytoplasmic N- and C-
termini (Canessa et al., 1994; Snyder et al., 1994). Alpha-ENaC
is expressed in epithelial tissues of the colon, kidney and lung,
whereas δ-ENaC is expressed in non-epithelial tissues of the
brain, eye, pancreas, ovary and testis (Waldmann et al., 1995;
Krueger et al., 2012). In lung epithelial cells, ENaC which are
highly, moderately and non-selective for Na+ compared to K+
ions, respectively, have been characterized (Jain et al., 1999,
2001).
Inherited diseases associated with mutations in ENaC which
increase or decrease channel activity testify to the important
role of ENaC in salt and water homeostasis. Liddle’s syndrome
(OMIM: 177200), is a severe form of hypertension associated
with ENaC hyperfunction brought about by mutations in the
PPxY motif within the β- and γ- subunits (Shimkets et al.,
1994; Hansson et al., 1995; Schild et al., 1995; Snyder et al.,
1995; Inoue et al., 1998), and pseudohypoaldosteronism type 1B
(PHA1B) (OMIM:264350), a rare, life-threatening, salt-wasting
syndrome caused by decreased ENaC function (Chang et al.,
1996; Strautnieks et al., 1996; Gründer et al., 1997; Boiko et al.,
2015). Mouse models of PHA1B have confirmed the critical
importance of individual ENaC subunits for fluid and salt
regulation in the lung and distal nephron. Alpha-ENaC knockout
mice die soon after birth from respiratory failure caused by
severely defective alveolar fluid clearance (Hummler et al., 1996);
whereas β- and γ-ENaC knockout mice die slightly later due to
severe electrolyte imbalance and hyperkalemia (Hummler et al.,
1997; Barker et al., 1998; McDonald et al., 1999; Pradervand
et al., 1999; Bonny and Hummler, 2000). Patients suffering
from PHA1B usually present in the first days of life with
failure to thrive, dehydration, low blood pressure, anorexia and
vomiting. Although hyperkalemia, hyponatremia and metabolic
acidosis in these patients suggest hypoaldosteronism, their
plasma aldosterone and renin activity are high. Children with
PHA1B suffer from respiratory tract infections, wheezing and
persistent rhinorrhea and some patients carrying mutations in
the α-ENaC gene have markedly increased liquid volume in
airway epithelia (Kerem et al., 1999; Thomas et al., 2002).
PHA1B does not improve with age and patients are at risk
from life-threatening, salt-losing crises, combined with severe
hyperkalemia and dehydration throughout their entire lives
(Zennaro and Lombès, 2004; Riepe, 2009).
The synthetically produced cyclic peptides solnatide (Lucas
et al., 1994) and its congener AP318 (Hazemi et al., 2010),
whose molecular structures mimic the lectin-like domain of
human tumor necrosis factor (TNF), have been shown to activate
ENaC in various cell- and animal-based studies (Shabbir et al.,
2013, 2015; Tzotzos et al., 2013). With the aim of investigating
whether the ENaC-activating effect of solnatide and AP318 could
rescue loss-of-function phenotype of ENaC carrying mutations
observed to cause PHA1B, Na+ currents elicited from mutant
ENaC in the presence of the peptides were measured in whole-
cell patch clamp experiments. The effect of the peptides on
membrane abundance of the mutant ENaCs was analyzed in
Western blotting experiments. Remarkably, both solnatide and
AP318 rescued loss-of-function ENaC in all mutants tested,
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restoring the amiloride-sensitive Na+ current to physiological
levels or even higher.
MATERIALS AND METHODS
Cell Culture
Human embryonic kidney HEK-293 cells (ATCC no. CRL-
1573) in passages 3–25, were seeded in Dulbecco’s modified
Eagle medium/F12 nutrient mixture Ham plus L-glutamine
(DMEM/F-12; GibcoTM by Life Technologies, LifeTech Austria),
supplemented with 10% fetal bovine serum (FBS; GibcoTM by Life
Technologies, LifeTech Austria) and 1% penicillin-streptomycin
(Sigma-Aldrich, Vienna, Austria). Cells were maintained at 37◦C
with 5% CO2 in a humidified incubator.
Molecular Biological Methods
cDNAs encoding α-, β-, and γ-hENaC were a kind gift from Dr.
Peter M. Snyder (University of Iowa, Carver College of Medicine,
Iowa City, USA).
Site-Directed Mutagenesis
Point mutations and single base (insertions or) deletions, causing
a frameshift, were introduced into cDNA encoding α-, β-, or γ-
hENaC using QuikChange Lightning Site-Directed Mutagenesis
Kit (Agilent Technologies, CA, USA). Pairs of mutagenic primers
were designed individually with the Primer Design Program
provided on the producer’s website. The same bases were changed
as reported in patients or at least resulting in the same protein
products. The designed primers were ordered after checking
their properties using the DNA Oligos Design Tool from Sigma-
Aldrich, Vienna, Austria (Table 1).
Mutant strands were synthesized by PCR with a Pfu-based
DNA polymerase using 100 ng wild type (WT) cDNA encoding
α-, β-, or γ-hENaC and the specific mutagenic primer pair.
Parental methylated and hemi-methylated template DNA was
digested with a Dpn I restriction enzyme for 5 min at 37◦C.
Transformation was performed with XL10-Gold ultracompetent
cells provided with the kit. Aliquots of the cells were treated with
β-mercaptoethanol for 2 min and incubated with the amplified
DNA for 30 min on ice. After 30 s of heat pulse at 42◦C and
2 min on ice, cells were grown in NZY+ broth (10 g NZ amine
(casein hydrolysate), 5 g yeast extract, 5 g NaCl, ddH2O added to
a final volume of 1 l, adjusted to pH 7.5 using NaOH, autoclaved,
addition of filter-sterilized 12.5 ml 1 M MgCl2, 12.5 ml 1 M
MgSO4, 10 ml 2 M glucose) for 1 h at 37
◦C with shaking at
250 rpm. Cells were centrifuged at 800 × g for 2 min and the
majority of the supernatant was discarded. The cell pellet was
resuspended in the remaining media and all cells were spread
on 60 mm LB agar (20 g LB broth, 15 g agar, ddH2O added to
a final volume of 1 l, autoclaved) plates containing 100 µg/ml
ampicillin (the appropriate antibiotic for the plasmid vector)
and incubated overnight (16–18 h) at 37◦C. Single colonies were
picked and cultured in LB broth (20 g LB broth, ddH2O added to
a final volume of 1 l, autoclaved) supplemented with 100 µg/ml
ampicillin overnight (16–18 h) at 37◦C with shaking at 250 rpm.
2 ml of the bacterial culture were used for DNA extraction; the
remaining cell suspension was mixed well with the same volume
TABLE 1 | Pairs of mutagenic primers for nine PHA1B mutations in
conserved regions of α-, β-, and γ-hENaC.
Mutation Primer sequence (5′-3′)
Alpha Q101K Forward: CATGATGTACTGGAAATTCGGCCTGC
Reverse: GCAGGCCGAATTTCCAGTACATCATG
Alpha C133Y Forward: CGCAGTGACCATCTACACCCTCAATCCC
Reverse: GGGATTGAGGGTGTAGATGGTCACTGCG
Alpha S243P Forward: GACATACTCTCCAGGGGTGGATGCGG
Reverse: CCGCATCCACCCCTGGAGAGTATGTC
Alpha G327C Forward: GGAATCAACAACTGTCTGTCCCTGATGC
Reverse: GCATCAGGGACAGACAGTTGTTGATTCC
Alpha S562L Forward: GGTTCGGCTCCTTGGTGTTGTCTGTGG
Reverse: CCACAGACAACACCAAGGAGCCGAACC
Alpha S562P Forward: GGTTCGGCTCCCCGGTGTTGTCTG
Reverse: CAGACAACACCGGGGAGCCGAACC
Alpha S243fs Forward: GACATACTCATCGGGGTGGATGCGG
Reverse: CCGCATCCACCCCGATGAGTATGTC
Beta G37S Forward: CACCAACACCCACAGCCCCAAGCGCAT
Reverse: ATGCGCTTGGGGCTGTGGGTGTTGGTG
Gamma V543fs Forward: GGATGAGCTGTTCTTTGTCTGCGTCATCG
Reverse: CGATGACGCAGACAAAGAACAGCTCATCC
of glycerol (Sigma-Aldrich, Vienna, Austria) and stored at−80◦C
in order to obtain a glycerol stock.
The DNA was extracted from Escherichia coli (E. coli) cells
with the GeneJET Plasmid Miniprep Kit (Thermo Scientific
Loughborough, UK) according to the producer’s protocol. The
cell pellet from 2ml overnight culture was resuspended, lysed and
neutralized. The supernatant was loaded to the column, washed
twice and the plasmid DNA was eluted. The DNA concentration
was measured with NanoDrop ND-1000 Spectrophotometer by
threefold determinations. In order to verify the presence of the
mutation the extracted DNA was sent to LGC Genomics GmbH,
Berlin, Germany, for sequencing. The sequencing result was
evaluated with the online available ExPASy Translate tool (http://
web.expasy.org/translate/).
Midi Prep
Glycerol stocks of E. coli colonies carrying positively mutated
cDNA were picked and cultivated in LB broth supplemented
with 100 µg/ml ampicillin. For larger amounts of DNA the
PlasmidMidi Kit (QIAGENGmbH, Hilden, Germany) was used.
The cell pellet from 100 ml overnight culture was resuspended,
lysed and neutralized. The supernatant was loaded to the
equilibrated column, washed twice and the plasmid DNA was
eluted. The DNAwas precipitated with isopropanol and the DNA
pellet was washed with 70% ethanol. The dry DNA pellet was
dissolved in elution buffer; the DNA concentration was measured
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with NanoDrop ND-1000 Spectrophotometer and diluted to a
concentration of about 600 ng/µl.
Transfection
HEK-293 cells were transfected 1 day after cell seeding using X-
tremeGENE HP DNA transfection reagent (Roche Diagnostics,
Mannheim, Germany) according to the manufacturer’s protocol.
A set of one mutant subunit and the other two WT subunits
of hENaC (250 ng cDNA per subunit for a 35 mm cell culture
dish) was used for each experiment and the ratio of DNA to
transfection reagent was 1:3. The expression was highest 48 to
72 h after transfection.
Cell Surface Biotinylation
HEK-293 cells were cultured in 100mm dishes in 5% CO2
incubator at 37◦C in DMEM medium supplemented with
5% FBS. Cells were harvested after reaching 90% confluency.
Solnatide and AP318 were added at a final concentration of
200 nM into the medium, and the cells were incubated for
5 or 10min. Then cells were washed 2× with 10ml cold
phosphate buffered saline (PBS), then treated with 10ml cold
PBS containing 2.5mg EZ-Link Sulfo-NHS-SS-Biotin (Thermo
Scientific, Rockford, USA), and incubated on ice with light
agitation for 30 min. Fifty ml quenching solution were added
to the cells. Cells were scraped and transferred to fresh 50ml
tube. The flask was rinsed with 10 ml Tris-buffered saline (TBS),
and also the rinsed volume was transferred to the present 50
ml tube. Cell suspension was centrifuged at 500 × g for 3 min
and supernatant was discarded. Five ml TBS was added to the
cell pellet. The cell pellet was resuspended, cell suspension was
centrifuged at 500 × g for 3 min, and also the supernatant
was discarded. Antipeptidase cocktail (10 µM pepstatin A, 10
µM phenylmethylsulfonyl fluoride and 10 µM leupeptin) was
added to lysis buffer that was applied to the cell pellet. Cells
were resuspended, transferred to 1.5 ml microcentrifuge tube
so homogenized on ice by ultrasonication using 1 s bursts. Cell
material was incubated on ice for 30 min. Intact cells and nuclei
were pelleted from the cell material by 10,000 × g for 2 min at
4◦C, processed supernatant was transferred to a fresh tube and
incubated overnight at 4◦C with 0.5 ml NeutrAvidin Agarose.
Then washed 3× with cell lysis buffer. The biotinylated proteins
were eluted with 100 µl sodium dodecyl sulfate (SDS) sample
buffer (62.5 mM Tris, pH 6.8, 1% SDS, 10% glycerine, 50 mM
dithiothreitol) containing 10 mM leupeptin. Trace amounts of
bromophenol blue were added to the eluates, and these eluates
were analyzed after heating for 10 min at 65◦C by SDS-PAGE and
immunoblotting.
Western Blotting
Corresponding amounts of protein were separated under
reducing conditions by SDS-PAGE on 7.5% SDS gels along
with color-coded prestained protein marker (cat. #12949 from
Cell Signaling). Proteins were transferred onto a nitrocellulose
membrane (UltraCruzTM 0.45 mm, Cat. # sc-3723 Santa Cruz
Biotechnology, Texas U.S.A) by tank blotting (Mini Trans-
Blot R© Transfer System, Bio-Rad Laboratories, Vienna, Austria)
at 100 V for 60 min. Non-specific binding sites were blocked by
incubation with 3% bovine serum albumin in PBS, supplemented
with 0.02% sodium azide, 1 h in room temperature and/or
overnight at 4◦C. Then the membranes were incubated with
primary antibody solutions (anti-α-ENaC NH2-terminal Cat.
# sc-22239, anti-β-COOH-terminal sc-22242, anti-γ-internal
region sc-22245 ENaC, and anti-β-tubulin antibodies from Santa
Cruz Biotechnology). Subsequently, membranes were washed 3x
with TBS containing 0.1% Tween 20 (TBST), and corresponding
horseradish peroxidase-conjugated secondary antibodies (Santa
Cruz Biotechnology) were applied. After incubation for 1.5 h at
room temperature and washing four times with TBST solution,
enhanced chemiluminescence (ECL) substrate (Amersham ECL
Plus Western Blotting Detection Reagent, GE Healthcare,
Vienna, Austria) was used for visualization. Following incubation
for 2 min, membranes were exposed to X-ray films (Amersham
Hyperfilm ECL, GEHealthcare). Exposed films were scanned and
quantified using ImageJ (NIH, Maryland, USA).
Electrophysiology
Whole-cell currents were recorded from transfected HEK-293
cells with an Axopatch 200B amplifier, DigiData 1440A and
pCLAMP10.2 software (Axon Instruments, Union City, CA)
at room temperature (19–22◦C) 48–72 h after transfection.
Currents were recorded at 10 kHz and filtered at 5 kHz.
The chamber contained 1 ml bath solution of the following
composition (in mM): 145 NaCl, 2.7 KCl, 1.8 CaCl2, 2 MgCl2,
5.5 glucose, and 10 HEPES, adjusted to pH 7.4 with 1 M
NaOH solution. The borosilicate glass patch pipettes (Harvard
Apparatus, Holliston, MA) had resistances of 2–4 M. The
pipette solution contained (in mM): 135 potassium methane
sulphonate, 10 KCl, 6 NaCl, 1Mg2ATP, 2 Na3ATP, 10 HEPES,
and 0.5 EGTA, adjusted to pH 7.2 with 1 M KOH solution.
Data acquisition and storage were processed directly to a PC.
After G-seal formation, the equilibration period of 5 min
was followed by recordings at a holding potential of −100
mV. Stock solutions (1 or 10 µM) of solnatide and AP318
were prepared with distilled water, and aliquots (2–20 µl)
were cumulatively added into the bathing solution, to reach
concentrations of 2–200 nM. Latest after 5 min steady state level
was reached and themean of 10 sweeps was taken for further data
analysis before adding the next higher concentration. The current
was measured continuously and the same clamp protocol was
applied during control recordings, and in presence of solnatide
or AP318. At the end of the experiments, 10 µM amiloride
was applied to show whether the peptide-induced increase in
current was due to the amiloride-sensitive Na+ current. The
amiloride-sensitive current was calculated by subtracting the
current in presence of amiloride from the current in absence
of amiloride and the solnatide- and AP318-induced current was
calculated by subtracting the current during control conditions
from the increased current after treatment with the respective
peptide. To analyze the role of glycosylation in solnatide-induced
activation of ENaC carrying PHA1B mutations the membrane
of transfected HEK-293 cells were deglycosylated with peptide-
N4-(N-acetyl-β-D-glucosaminyl)asparagine amidase F (PNGase
F, peptide N-glycanase). Cells were incubated with PNGase
F (100 U) immediately prior to patch-clamp experiments, as
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previously described by Shabbir et al. (2013). Data was analyzed
with OriginPro 2017 (OriginLab, Northampton, MA, USA) and
figures were edited with CorelDRAW X7 (Corel Corporation,
Ottawa, ON, Canada). Data are represented as mean ± SEM.
Differences were evaluated by one-way ANOVA followed by
Tukey’s post-hoc test.
Test Compounds
Solnatide (CAS Registry Number: 259206-53-6; CA Index
Name: L-cysteine, L-cysteinylglycyl-L-glutaminyl-L-arginyl-L-
.alpha.-glutamyl-L-threonyl-L-prolyl-L-.al-pha.-glutamylglycyl-
L-alanyl-L-.alpha.-glutamyl-L-alanyl-L-lysyl-L-prolyl-L-
tryptophyl-L-tyrosyl-, cyclic (1.fwdarw.17)-disulphide) with the
amino acid sequence CGQRETPEGAEAKPWYC, and AP318
(Cyclo(4-aminobutanoic acid-GQRETPEGAEAKPWYD))
are derived from the lectin-like domain of TNF
(CQRETPEGAEAKPWYE), and are also called TIP peptides.
Synthesis and description of the peptides is reported in detail by
Hazemi et al. (2010). All chemicals, reagents and culture media
were obtained from Sigma-Aldrich (Vienna, Austria), unless
stated otherwise. See Figure 1 for molecular models of solnatide
and AP318 (see also Hazemi et al., 2010).
RESULTS
The ability of the cyclic peptides solnatide and AP318 to activate
ENaC harboring PHA1B-causing mutations was tested, in order
to identify novel therapeutic candidates for PHA1B treatment.
The only difference between solnatide and AP318 is that the
disulphide bridge between cysteines in positions 1 and 17 and
which links the N- and C-termini in solnatide has been replaced
by an amide bond linking the amino group of 4-amino-butanoic
acid in position 1 with the side chain carboxyl group of aspartic
acid in position 17 (Figure 1).
Mutations in α-, β-, and γ-subunits of ENaC associated with
PHA1B are described in the literature; there are no reports of
PHA1B-causing mutations in δ-ENaC. In this work mutations
which occur at residues conserved in all four subunits of
hENaC, and which have been confirmed by genetic analysis
of patients diagnosed with PHA1B, were reconstructed and
studied regarding their macroscopic current and membrane
abundance. Conserved regions seem to play an integral role
in the functionality of the channels, which makes them appear
particularly relevant to be observed in the first instance.
The βG37S mutation, which is equivalent to G70 in the α-
subunit and has been electrophysiologically characterized before
(Chang et al., 1996; Gründer et al., 1997; Kucher et al., 2011), is
located intracellularly in the N-terminal region of the polypeptide
chain (Figure 2A). The αQ101K mutation is located in the first
transmembrane region TM1 of α-ENaC toward the extracellular
side (Mora-Lopez et al., 2012).Mutations in the extracellular loop
can be assigned to domains as defined by Jasti et al. (2007) for
the X-ray structure of the chicken acid-sensing channel (ASIC1),
a homolog of ENaC. The αC133Y mutation (Bonny et al., 1999)
lies in the core of the extracellular loop, within the β-ball (colored
orange in Figure 2B). Mutations αS243P (Dirlewanger et al.,
2011) and αS243fs (Schaedel et al., 1999) lie in the finger (colored
blue in Figure 2B), rather exposed in the extracellular loop. The
frameshift at this position results in a premature stop codon
only four amino acids after the affected S residue. The αG327C
mutation (Edelheit et al., 2005) lies within the palm domain
(colored yellow in Figure 2B) at the boundary with the β-ball
and αS562L (Schaedel et al., 1999) and αS562P (Riepe et al.,
2009) lie within the TM2 region. The γV543fs mutation (Adachi
et al., 2001), which is equivalent to V563 in the α-subunit, is
similarly located within the TM2 domain. The γV543fs mutation
is predicted to result in synthesis of a truncated translation
product of 597 amino acid residues with an abnormal (non-WT)
sequence after S542.
To study the channel function, combinations of αβγ-ENaC
comprising one mutant and two WT chains were expressed in
HEK-293 cells and the amiloride-sensitive Na+ current in the
whole-cell mode was recorded. All investigated ENaC carrying
PHA1B mutations showed a lower control current than WT
ENaC (Figure 3), which is likely to be the cause of the disease.
All tested control and solnatide- or AP318-induced currents
of HEK-293 cells transfected with WT or mutant ENaC were
amiloride-sensitive and were significantly higher than whole-cell
current of mock-transfected HEK-293 cells, and therefore can
be identified as ENaC-current. The control current of mock-
transfected cells was 11.28 ± 5.68 pA and did not change after
10 µM amiloride (10.47 ± 6.23 pA), 200 nM solnatide (11.24 ±
3.01 pA) or 200 nM AP318 (11.59 ± 1.24 pA) treatment, so the
amiloride-sensitive and solnatide- or AP318-induced current of
mock-transfected HEK-293 cells was about zero.
Both solnatide and AP318 enhanced amiloride-sensitive Na+
current in a concentration dependent manner, although the
EC50-values of most mutants were higher compared to WT
(Table 2). This is most likely due to the changed tertiary structure
and subunit assembly of mutant ENaC and therefore a poorer
accessibility of the binding sites of the peptides. At 200 nM of
solnatide or AP318, a maximum current increase was observed
in WT ENaC and in all mutants, which can be seen in the dose-
response-curve of solnatide and AP318 of the αC133Y mutant
as an example (Figure 11C) or in the time-dependent activation
curve of WT ENaC with solnatide and AP318 (Figures 5A,B).
Both peptides restored the current to physiological values of
WT control or even higher (Figure 4). Notably, AP318 elicited
a higher maximum current compared to solnatide (compare
Figures 4A,B) and showed lower EC50-values (Table 2) for
mutant and WT αβγ-ENaC. The major differences between
solnatide and AP318 are the replacement of terminal cysteines
of solnatide with 4-aminobutanoic and aspartic acid residues and
the consequent absence of a positively-charged N-terminal group
in AP318. This difference in chemical structure apparently results
in an increased potency of AP318 compared to solnatide.
For further investigation the macroscopic Na+ current and
membrane abundance of ENaC carrying PHA1B mutations
before and after treatment with solnatide and AP318 were set
in relation to WT control (Figures 6, 7, 9, 12). Original trace
recordings are shown for one mutation in each ENaC subunit
(Figures 8, 10, 11). Additionally an example of a dose-response-
curve of solnatide and AP318 of the αC133Y mutant was
included into Figure 11C.
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FIGURE 1 | Structure of solnatide (AP301) and AP318. Peptides were modeled according to a previously described protocol (Hazemi et al., 2010) using the
crystal structure of TNFα, PDB ID: 3L9J (Byla et al., 2010), as a template and rendered using the molecular graphics program Chimera, version 1.10.2 (Pettersen
et al., 2004). Abu, 4-aminobutanoic acid.
FIGURE 2 | PHA1B mutants mapped onto ENaC. (A) Topology model of
α-ENaC subunit showing approximate location of PHA1B mutations in primary
sequence, and mutations in β- and γ-subunits in brackets. (B) Homology
model of mouse α-ENaC extracellular domain (Kashlan et al., 2011), with
residues equivalent to those in human α-ENaC which are the sites of PHA1B
mutations highlighted (pink with ball and stick rendering of side chains);
residue numbering is for mouse α-ENaC (UniProt Q61180, SCNNA_MOUSE)
with equivalent residue numbers of human α-ENaC (UniProt P37088,
SCNNA_HUMAN) in brackets; color of the backbone ribbon indicates the
approximate location of domains in the ASIC1 structure according to Jasti
et al. (2007), viz: “palm,” yellow; “β-ball,” orange; “finger,” blue; “thumb,”
green; “knuckle,” cyan. Graphic created using Chimera, version 1.10.2
(Pettersen et al., 2004).
Since the glycosylation sites of α-ENaC have been shown to
be essential for the activating effect of solnatide (Shabbir et al.,
2013, 2015), it was tested, whether this is still the case for PHA1B
mutant ENaC. Therefore, the effect of solnatide was tested
exemplarily on some mutants after treatment with PNGase F,
which deglycosylates the cell membrane of the transfected HEK-
293 cells. Solnatide had no effect on these mutant ENaCs after
deglycosylation (Figure 11D), similar to the results observed
previously for WT ENaC (Shabbir et al., 2013).
FIGURE 3 | PHA1B-causing mutations in hENaC exhibit low current.
Mean values of (10 µM) amiloride-sensitive Na+ current in HEK-293 cells
expressing WT hENaC (empty bar) and PHA1B-causing mutations in either α-
(filled or hatched, black bars), β- (filled, light gray bar) or γ- (hatched, dark gray
bar) hENaC subunits are shown. Point mutations are indicated with filled bars,
whereas frameshift mutations are indicated with hatched bars. WT or mutant
hENaC were patched in the whole-cell mode; inward current was elicited at
−100 mV. All mutants showed a significant decrease in current vs. WT ENaC,
***p < 0.001 (n = 6–13).
Mutations are discussed below according to three themes: (1)
effect of mutations in the two TM regions of ENaC, namely
αQ101K, αS562L, αS562P, and γV543fs; (2) effect of frameshift
mutations compared to point mutations; and (3) effect of
mutations in non-TM regions, namely αC133Y, αG327C, and
βG37S.
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PHA1B Mutations in TM Regions
ENaC carrying the αQ101K and γV543fs mutations showed
a very low control current indicating severe loss-of-function;
αS562L and αS562P, on the other hand showed about half of
the WT control current, a moderate decrease compared to the
other mutations (Figure 3). As mentioned above solnatide and
AP318 were able to rescue all the mutants. The fold increase of
current in the αQ101K and γV543fs mutations are about 8-fold
for solnatide and 9-fold for AP318, similar to WT ENaC (10-fold
increase with solnatide and 11-fold with AP318; compare Shabbir
et al., 2013). The αS562L mutant shows an approximately 2-fold
increase with solnatide and 3-fold with AP318, and αS562P 4-
fold with solnatide and 5-fold with AP318. Remarkably, the cell
surface expression of αQ101K was far higher than WT control
TABLE 2 | EC50-values for solnatide and AP318 in WT and mutant ENaC.
Construct Solnatide EC50 (nM) AP318 EC50 (nM)
Wild type 52.4 ± 3.7 29.3 ± 4.4
αQ101K 64.5 ± 3.5* 37.4 ± 1.7
αC133Y 74.0 ± 6.8*** 42.1 ± 2.4**
αS243P 80.1 ± 12.9*** 49.3 ± 5.8***
αG327C 50.2 ± 5.2 26.1 ± 2.9
αS562L 64.3 ± 6.3 46.4 ± 2.9***
αS562P 61.1 ± 8.9 49.3 ± 3.1***
αS243fs 72.8 ± 1.3** 38.9 ± 6.5
βG37S 65.8 ± 3.2* 36.7 ± 6.0
γV543fs 58.4 ± 7.9 47.7 ± 4.1***
Mean values ± SEM of 3–8 independent experiments are given. Significant differences
compared to WT are indicated, *p < 0.05, **p < 0.01, ***p < 0.001.
and even increased after 5 min treatment with solnatide and
AP318 (Figure 6). After 10 min treatment with both peptides
the surface expression of αQ101K is decreased, but still higher
than WT. The whole-cell current is rather unaffected by the
changed membrane abundance and is consistently increased at
least for 10 min after treatment with solnatide (Figure 5C). The
αS562P mutation also showed increased membrane abundance
in control and after short-term exposure to solnatide and AP318.
In contrast the expression of αS562L remained unchanged
compared to WT, with membrane abundance increasing only
after 5 min in the presence of AP318 (Figure 7). For comparison,
the surface expression of WT α-ENaC showed a 1.5-fold increase
after 5 min treatment with solnatide and 1.4-fold with AP318,
when co-expressed with WT βγ-subunits (see Table 3). The
surface expression of γV543fs—but also of WT γ-ENaC (see also
Shabbir et al., 2015)—did not increase significantly, when set in
relation to respective β-tubulin quantity (Figure 8).
Effect of Solnatide and AP318 on Point vs.
Frameshift Mutations
The ENaC mutant αS243P showed a very low control current,
whereas the macroscopic Na+ current of the frameshift mutation
at the same position was only slightly reduced compared to WT.
The current activation by solnatide and AP318 looked similar
for both mutations, when compared to the respective control
current. The fold activation for both mutations and peptides
is around 3-fold. While the αS243P mutation showed a very
low surface expression, which was only slightly, but significantly
increased after 10 min by solnatide and AP318 and did not
reach the WT value, the αS243fs mutation had an increased
membrane abundance without and even higher with solnatide
and AP318 (Figure 9). The control surface expression of αS243fs
FIGURE 4 | Both solnatide and AP318 activate macroscopic current reaching to WT (control) in PHA1B mutations. Mean data of 200 nM solnatide- (A) and
AP318- (B) induced Na+ current in HEK-293 cells expressing hENaC harboring PHA1B-causing mutations in either α- (filled or hatched, black bars), β- (filled, light
gray bar) or γ- (hatched, dark gray bar) subunits are shown. Point mutations are indicated with filled bars, whereas frameshift mutations are indicated with hatched
bars. For comparison with the (10 µM) amiloride-sensitive current of WT hENaC (without treatment) (empty bar) solid line is shown. All PHA1B mutants showed
currents equal to/more than WT hENaC followed by solnatide and AP318 treatments (amiloride-sensitive current of WT: n = 13; solnatide- and AP318-induced
current of mutant ENaC: n = 3–8). Significant differences compared to WT control are indicated, *p < 0.05, **p < 0.01, ***p < 0.001.
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FIGURE 5 | Time course of current activation of ENaC with solnatide and AP318. Dose-response relationship for solnatide (A) and AP318 (B) on WT ENaC is
shown in a time-dependent manner. Both peptides were applied at increasing concentrations from 1.56 to 200 nM at indicated time points (arrows). For each
concentration only the current amplitude during steady state levels were used for further analysis. Additionally the time course of activation of αQ101K by solnatide (C)
and of αG327C by AP318 (D) is shown. The activation is rapid and consistent at least for 10 min of treatment with peptides and can be blocked by 10 µM amiloride.
The time points of peptide and amiloride addition are marked by arrows. The whole-cell current of transiently transfected HEK-293 cells was measured continuously;
n = 3–5.
was even higher than WT α-ENaC after treatment with solnatide
and AP318 (Table 3). Worth mentioning in Western blot of
biotinylated surface proteins from HEK-293 cells transiently
transfected with αS243fsβγ-ENaC a band was observed at about
30 kDa, which corresponds with the expected size 28.6 kDa of
the truncated α-ENaC (theoretical protein length: 247 amino
acids).
Non-TM PHA1B Mutations
The control current of the βG37S mutant was low, but increased
after treatment with solnatide and AP318. The fold increase with
solnatide is about 7-fold and with AP318 5-fold. The surface
expression of βG37S showed no appreciable change compared
to WT, but after 5 min treatment with solnatide a high increase
was observed (Figure 10), which is particularly interesting since
in previous studies the surface expression of WT β-ENaC was
not affected by solnatide (Shabbir et al., 2015). The macroscopic
Na+ current of αC133Y was reduced compared to WT control
and could be rescued by solnatide and AP318, the fold increase
for solnatide being about 2-fold and for AP318 3.3-fold. The
membrane abundance of αC133Y was higher than WT control
and even higher than WT after treatment with solnatide and
AP318 (Table 3), and increased after 5 min of AP318 treatment
(Figure 11). The control current of αG327C was decreased as in
all tested PHA1B mutations, but it showed the highest increase
in current among all investigated mutations after treatment with
AP318 (Figure 4). Also among all testedmutations it was the only
one, on which both peptides did not change their EC50-values
compared to the WT channel (Table 2). Nevertheless, the fold
increase around 6-fold for both peptides is lower than the 10-fold
increase of WT current after treatment with solnatide and 11-
fold with AP318. Themembrane abundance was highly increased
and further increased upon treatment with AP318 after 5 min
(Figure 12). After 10 min treatment with both peptides the cell
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FIGURE 6 | Both solnatide and AP318 activate macroscopic Na+
current and increase membrane abundance. (A) A typical Western blot
out of four with biotinylated surface proteins of HEK-293 cells transiently
transfected with WT or αQ101K mutant ENaC and treated with solnatide or
AP318 at indicated time points is shown, using α-ENaC and β-tubulin
antibodies. (B) Solnatide- (200 nM, gray bar) and AP318- (200 nM, black bar)
induced current in αQ101K was normalized relative to WT control (empty bar).
Mean values ± SEM of 6–13 experiments are given. Membrane abundance
was increased without (empty bar) and with 200 nM solnatide (gray bars) and
AP318 (black bars) at indicated time points (5′ or 10′). Expression of αQ101K
ENaC was quantified relative to β-tubulin from Western blots using four
independent biological replicates. Significant differences are indicated, *p <
0.05, **p < 0.01, ***p < 0.001.
surface expression of αG327C decreased, but is still higher than
WT α-ENaC. This time-dependent change of expression does not
influence the measured whole-cell current, which is consistently
increased at least for 10 min after treatment with AP318
(Figure 5D).
In summary, the macroscopic Na+ currents of all investigated
conserved PHA1B mutants were decreased, and could be
activated by treatment with solnatide or AP318 up to or
FIGURE 7 | Solnatide and AP318 show similarity in macroscopic
current activation but difference in membrane abundance of ENaC
PHA1B mutations at same position. The macroscopic Na+ current (I
(pA/pF)) of αS562L (A) and αS562P (B) mutation without (empty bars) and
with treatment with 200 nM solnatide (gray bars) and AP318 (black bars) was
normalized relative to WT control (empty bars). Both PHA1B mutations at this
position of ENaC show a reduced control current compared to WT and
treatment with solnatide and AP318 increased the current higher than WT
control (n = 4–13). The expression of α-ENaC was quantified relative to
β-tubulin from Western blots using three independent biological replicates
each, and the membrane abundance (expression) of αS562L (A) and αS562P
(B) without or with treatment with solnatide and AP318 at indicated time
points was set in relation to WT control. Significant differences are indicated,
**p < 0.01, ***p < 0.001.
even higher than the WT control level. A greater variation
among the mutations was observed regarding their membrane
abundance. The surface expression of some mutants like
αS243P was sharply reduced, while the membrane abundance of
others, like αQ101K was markedly increased. While the surface
expression of WT channel was increased approximately 1.4-fold
by solnatide and AP318, the peptides apparently had no effect
on membrane abundance of some PHA1B mutants but a greater
effect compared to WT on others. For the most mutants of
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FIGURE 8 | Solnatide and AP318 activate ENaC currents, but not membrane abundance of γV543fs. (A) Superimposed representative whole-cell current
traces of αβγV543fs ENaC in absence (γV543fs control) and presence of 10 µM amiloride, 200 nM solnatide and 200 nM AP318 are shown as well as WT ENaC
control. HEK-293 cells transfected with WT or mutant ENaC channel construct were patched in the whole-cell mode; inward current was elicited at −100 mV (n =
3–6). (B) Biotinylated proteins from cellular extracts of HEK-293 cells (∼15 µg) transiently transfected with WT or PHA1B mutant αβγV543fs ENaC were treated with
solnatide and AP318 at indicated time points, and were subjected to SDS/PAGE and immunoblotting analysis with γ-ENaC and β-tubulin antibodies. A typical blot out
of five independent biological replications is shown.
α-ENaC (e.g., αQ101K and αG327C) the membrane abundance
is decreased after 10 min of solnatide and AP318 treatment
(Table 3). A similar effect was reported for WT ENaC by Shabbir
et al. (2015), where the highest surface expression of α-ENaC
was observed after 5 min of solnatide treatment and after 10
and 30 min the expression decreases again, but is still higher
than control. The effect of solnatide and AP318 on the cell
surface expression of WT or mutant ENaC is very rapid and
transient; therefore it is unlikely that the observed effect is due
to transcription of ENaC genes. More likely ENaC channels
are translocated from the Golgi apparatus to the cell surface
membrane or the degradation of ENaC mediated by Nedd4-2
is inhibited. Remarkably, the observed solnatide- and AP318-
induced current was not (only) caused by increased membrane
abundance of ENaC channels, but the peptides additionally
increase the open probability, Po of ENaC persistently, which has
already been shown for WT ENaC channels (Shabbir et al., 2013,
2015). These two effects seem to occur by different mechanisms,
because the peptides affect the membrane abundance of ENaC
only for a short time of 5 or 10 min; at longer exposure times the
values return to control; whereas the ENaC-current is increased
persistently. As shown by Lucas et al. (2016), the open probability
ofWTENaC transiently transfected inH441 cells is still increased
15 min after addition of solnatide (TIP peptide). In primary
alveolar epithelial type II cells and additionally in A549 cells,
endogenously expressing ENaC, solnatide was able to increase the
whole-cell current consistently for about 15 min (Tzotzos et al.,
2013). Although some PHA1B mutants showed a different—
for some mutants even stronger—time-dependent effect of
solnatide and AP318 on the membrane abundance compared
to WT ENaC, the peptide-induced increase in current was still
persistent at least for 10 min of peptide treatment, as exemplarily
shown for αQ101K (Figure 5C) and αG327C (Figure 5D).
Secondly, some mutations do not show an increase in membrane
abundance after treatment with solnatide and AP318, but
currents of all mutant ENaC constructs are activated by the
peptides.
DISCUSSION
The widespread tissue distribution of ion channels and the
diversity of their physiological functions, gives rise to a range
of channelopathies caused by mutations in genes encoding
ion channel subunits, or their interacting proteins. For most
channelopathies described to date, therapy is mainly empirical
and symptomatic, often limited by lack of efficacy and
tolerability. Nevertheless, despite the potential of ion channels as
drug targets, relatively few marketed drugs have ion channels as
their primary target. PHA1B is a rare, life-threatening, inherited,
salt-wasting disease which is associated with mutations in ENaC
resulting in a decrease of channel activity. Previously, solnatide
was shown to increase ENaC activity in A549 and H441 cells
(Hazemi et al., 2010; Shabbir et al., 2013; Czikora et al., 2014),
freshly isolated type II alveolar epithelial cells from different
species (Tzotzos et al., 2013) and heterologously expressed
human ENaC subunits (Shabbir et al., 2013, 2015). A similar
pronounced increase in ENaC activity with an even smaller EC50-
value was observed with AP318 in A549 cells (Hazemi et al., 2010;
Shabbir et al., 2013). Hence we intended to prove whether this
ENaC-activating effect applies to mutated ENaC which causes
PHA1B. It was demonstrated that αβγ- (Canessa et al., 1994;
Edelheit et al., 2011) or δβγ-ENaC subunit coexpression (Shabbir
et al., 2013) was essential for maximal activity in control as well
as treatment with solnatide (Shabbir et al., 2013). Thus, in our
experiments we always co-expressed the specific mutated subunit
together with the two appropriate WT subunits, to achieve
heterooligomeric ENaC expression.
Effect of TIP Peptides on ENaC Carrying
Mutations in TM Regions
According to homology with chicken ASIC1 (Jasti et al., 2007),
the point mutations αQ101K, αS562L, αS562P are situated in the
transmembrane regions TM1 (F86-F106) and TM2 (M544-L577,
equivalent to V427-I460 in ASIC1) of α-hENaC. AlphaQ101K
lies within TM1, five residues from the extracellular surface of
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FIGURE 9 | Point and frameshift mutation show different current
activation and membrane abundance after treatment with solnatide
and AP318. The macroscopic Na+ current (I (pA/pF)) of αS243P (A) and
αS243fs (B) PHA1B mutation without (empty bars) and with treatment with
200 nM solnatide (gray bars) and AP318 (black bars) was normalized relative to
WT control (empty bars) (n = 3–13). The control currents of both mutations at
the same position of ENaC are reduced compared to WT and can be rescued
by solnatide and AP318. The expression of α-ENaC was quantified relative to
β-tubulin from Western blots using four independent biological replicates each,
and the membrane abundance (expression) of αS243P (A) and αS243fs (B)
without or with treatment with solnatide and AP318 at indicated time points
was set in relation to WT control. The surface expression of αS243P is
reduced and only improved after 10 min treatment with solnatide and AP318,
whereas the membrane abundance of αS243fs is more than double compared
to WT control and further enhanced by solnatide and AP318 treatment.
Significant differences are indicated, *p < 0.05, **p < 0.01, ***p < 0.001.
the membrane, whereas the mutations αS562L and αS562P occur
in the lower middle of TM2.
In our experiments amiloride-sensitive Na+ current
was significantly lower in mutants situated in or near the
transmembrane regions compared to WT ENaC. Our findings
thus confirm those of Boiko et al. (2015) for the αS562P
mutant who recorded almost no current in this mutant. In the
case of αQ101K, αS562L, and αS562P mutants, the two test
compounds, solnatide and AP318, were able to increase the
amiloride-sensitive Na+ current to WT control level or even
above, AP318 showing even higher activity than solnatide.
However, membrane abundance differed markedly among these
mutants. While membrane expression of αQ101K and αS562P
was significantly increased in control, expression of αS562L was
almost unaffected. Both TIP peptides caused a transient increase
in membrane abundance of αQ101K and αS562P, but not of the
αS562L mutant.
Q101 is part of the highly conserved “YWQF” motif, and
sequence alignment shows that the “YWQF” motif is conserved
in different ENaC subunits and species (Mora-Lopez et al., 2012).
In the case of NMDA receptors it could be demonstrated that
the “YWQF” motif is necessary and sufficient to drive their
internalization (Scott et al., 2004; Lau and Zukin, 2007). This
motif likely plays a similar role in other ion channels. So,
it might also be involved in driving ENaC to internalization
and degradation in endosomes. According to this hypothesis,
disruption of the “YWQF” motif would result in accumulation
of ENaC subunits in the membrane, which could explain our
findings of increased membrane abundance of mutant α-subunit
in the case of the αQ101K mutant.
Previous studies have shown that selected mutations within
the TM2 tract have dramatic effects on channel gating
(Waldmann et al., 1995; Snyder et al., 2000). Mutagenesis studies
support the concept that the selectivity filter of ENaC involves
three conserved amino acids, G/SxS in the middle of the TM2
segment in α-, β-, and γ-subunits. S562 is the third residue
of the “GSS” selectivity motif described by Kellenberger et al.
(2001). The authors reported that mutation of S589 in rat α-
ENaC, (equivalent to S562 in human α-ENaC), caused loss of
ENaC function. So, the in vitro study reflected the in vivo
report of the human mutation which causes PHA1B (Schaedel
et al., 1999). The mutation S562P was found in a Somalian
family with the typical systemic PHA1B phenotype. The role
of residues homologous to αS562 for the ionic selectivity of
other ENaC/DEG channels such as DEG-1 (Garcia-Anoveros
et al., 1995), MEC-4 (Hong and Driscoll, 1994), and ASIC2a
(Waldmann et al., 1996) clearly points to their critical roles in
ENaC function. Together with the corresponding residues in
the β- and γ-ENaC subunits, S562 forms the ENaC selectivity
filter (Kellenberger et al., 1999a,b), lining the channel pore at
its narrowest part. Our findings for the αS562P mutation are
consistent with published data which revealed a dramatic loss-
of-function of the mutant in in vitro expression (Boiko et al.,
2015). It is assumed that reduced ion conduction is likely due
to structural changes in the critical region of the selectivity
filter. Contrary to Riepe (2009) who found similar membrane
expression of this mutant, we observed a significant increase
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FIGURE 10 | Both solnatide and AP318 activate ENaC currents, but only solnatide increases membrane abundance in βG37S. (A) Superimposed
representative whole-cell current traces of αβG37Sγ ENaC in absence (βG37S control) and presence of 10 µM amiloride, 200 nM solnatide and 200 nM AP318 are
shown as well as WT ENaC control. The HEK-293 cells transfected with indicated ENaC channel construct were patched in the whole-cell mode; inward current was
elicited at −100 mV (n = 5–13). (B) Biotinylated proteins from cellular extracts of HEK-293 cells (∼15 µg) transiently transfected with WT or PHA1B mutant αβG37Sγ
ENaC were treated with maximum current activating solnatide and AP318 concentrations at indicated time points, and were subjected to SDS/PAGE and
immunoblotting analysis with β-ENaC and β-tubulin antibodies. A typical blot out of five independent biological replications is shown.
FIGURE 11 | Original recordings of patch-clamp and Western blot experiments, dose-response-curve of solnatide and AP318 and the effect of
deglycosylation on the current activation of αC133Y. (A) Superimposed representative whole-cell current traces of αC133Yβγ ENaC in absence (αC133Y control)
and presence of 10 µM amiloride, 200 nM solnatide and 200 nM AP318 are shown as well as WT ENaC control. HEK-293 cells transfected with WT or mutant ENaC
channel construct were patched in the whole-cell mode; inward current was elicited at −100 mV (n = 3–13). (B) Biotinylated proteins from cellular extracts of
HEK-293 cells (∼15 µg) transiently transfected with WT or PHA1B mutant αC133Yβγ ENaC were treated with maximum current activating solnatide and AP318
concentrations at indicated time points, and were subjected to SDS/PAGE and immunoblotting analysis with α-ENaC and β-tubulin antibodies. A typical blot out of
five independent biological replications is shown. (C) A dose-response-curve of solnatide and AP318 was obtained by cumulatively adding one of the peptides into
the bath solution during patch-clamp experiments. Solnatide: n = 5; AP318: n = 3. (D) After treatment with PNGase F, which deglycosylates ENaC, no effect of
solnatide can be observed in whole-cell patch-clamp experiments with αC133Y and αS562P mutants, n = 3.
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FIGURE 12 | Both solnatide and AP318 activate macroscopic Na+
current, but only AP318 increases membrane abundance. (A) A typical
Western blot out of three with biotinylated surface proteins of HEK-293 cells
transiently transfected with WT or αG327C mutant ENaC and treated with
solnatide or AP318 at indicated time points is shown, using α-ENaC and
β-tubulin antibodies. (B) The current of αG327C without (empty bar) and with
treatment with 200 nM solnatide (gray bar) and AP318 (black bar) was
normalized relative to WT control (empty bar) (n = 4–13). The control current is
reduced compared to WT and can be rescued by solnatide and AP318.
Membrane abundance was increased without (empty bar) and with 200 nM
solnatide (gray bars) and AP318 (black bars) at indicated time points (5′ or 10′)
compared to WT control. The expression of α-ENaC was quantified relative to
β-tubulin from Western blots using three independent biological replicates.
Significant differences are indicated, ***p < 0.001.
in expression of αS562P compared to WT ENaC, whereas
membrane abundance was not significantly changed in the
αS562L mutant. This discrepancy between these two mutants
at position 562 regarding membrane abundance might be due
to physico-chemical properties of the amino acids. Riepe (2009)
reported that artificial mutation of S562 changing serine to amino
acids of similar sizes make ENaC permeable for larger ions,
whereas substitution of S562 with aromatic residues inactivates
the channel. Both substituted amino acids, proline in the S562P
and leucine in the S562L mutants, are non-polar and neutral,
but differ in hydrophobicity and van-der-Waals volume. The
substitution of the polar residue serine for the non-polar proline
would introduce rigidity into the polypeptide chain and render
it inflexible, whereas the introduction of leucine with its bulky
hydrophobic side chain would bring about steric hindrance
compared to the smaller, polar side chain of the WT serine.
Both TIP peptides increased the reduced current in αS562L
as well as αS562P above WT ENaC levels, but whereas both
TIP peptides transiently enhanced membrane abundance in the
αS562P mutant, in the αS562L mutant only AP318 caused a
transient increase of membrane expression. Solnatide has been
shown to activate ENaC upon binding to a domain between the
TM2 and the carboxyl terminus of the α-subunit of the channel
(Czikora et al., 2014; Lucas et al., 2016), and apparently this
binding was not prevented by these mutations located in TM2,
so that current could be restored to WT levels or above.
For γ-hENaC, sequence alignment with chicken ASIC1
specifies the residues I524-E551 for TM2, because after E551
(equivalent to D454 in chicken ASIC1) significant sequence
similarity between chicken ASIC1 and γ-hENaC is not detectable.
According to this interpretation, the frameshift mutation
γV543fs lies at the lower part of TM2 eight residues away
from the intracellular surface of the membrane, which is also
within the TM2 range of the model published by Stockand
et al. (2008). Interestingly residue S542, preceding V543 in γ-
ENaC, is the equivalent residue to S562 in α-ENaC, which is
the third residue of the selectivity filter “GSS” motif in the α-
subunit as discussed above. Thus, V543 lies adjacent to the
“selectivity filter” in γ-hENaC, which could explain why γV543fs
affects ENaC function. Indeed, in control conditions current was
markedly decreased compared to WT ENaC, whereas membrane
abundance remained almost unchanged. Nonetheless, in the
γV543fs mutant amiloride-sensitive current and membrane
abundance were significantly increased by both test compounds.
Thus, it can be assumed that after binding to glycosylation sites
(Shabbir et al., 2015) solnatide (Lucas et al., 2016) and AP318
still can interact with the C-terminal domain of the α-subunit in
the γV543fs mutant ENaC heterooligomer and increase current
in this way, although to a lesser extent than in WT ENaC. This
confirms our findings in WT ENaC which showed that solnatide
activates current in the dual αβ-ENaC subunit combination to
a similar extent (Shabbir et al., 2013) as observed in γV543fs
co-expressed with αβ-ENaC subunits.
Effect of TIP Peptides on Point vs.
Frameshift Mutation
Point mutation αS243P and frameshift mutant αS243fs are
located within the finger domain of ENaC. The finger domain
shows the least sequence conservation within the ENaC/DEG
family (Jasti et al., 2007). This sequence variability is believed to
reflect the ability of members of the ENaC/DEG family of ion
channels to respond to a variety of extracellular signals which
affect channel opening or closing. In this sense the finger domains
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TABLE 3 | Membrane abundance of WT and mutant ENaC without and with 5 and 10 min treatment with solnatide and AP318.
Mutation Control Solnatide AP318
5 min 10 min 5 min 10 min
Wild type 1 1.46 ± 0.12** 1.34 ± 0.23 1.41 ± 0.13** 1.38 ± 0.16*
αQ101K 3.48 ± 0.09††† 4.58 ± 0.06*** 2.58 ± 0.17** 4.12 ± 0.23* 2.65 ± 0.05***
αC133Y 2.25 ± 0.14††† 1.89 ± 0.04* 1.51 ± 0.08** 3.84 ± 0.16*** 1.28 ± 0.05***
αS243P 0.11 ± 0.05††† 0.18 ± 0.07 0.56 ± 0.13** 0.09 ± 0.14 0.32 ± 0.08*
αG327C 3.15 ± 0.18††† 2.97 ± 0.14 1.82 ± 0.11*** 4.66 ± 0.21*** 1.67 ± 0.07***
αS562L 0.82 ± 0.25 0.74 ± 0.27 0.91 ± 0.21 2.15 ± 0.13*** 0.93 ± 0.14
αS562P 2.43 ± 0.25††† 3.68 ± 0.17** 1.82 ± 0.22 2.89 ± 0.12 2.13 ± 0.16
αS243fs 2.23 ± 0.15††† 4.25 ± 0.21*** 3.82 ± 0.15*** 4.13 ± 0.27*** 3.99 ± 0.13***
βG37S 0.86 ± 0.15 3.47 ± 0.26*** 0.84 ± 0.15 0.74 ± 0.26 0.56 ± 0.08
γV543fs 1.11 ± 0.15 1.32 ± 0.19 0.44 ± 0.12** 1.41 ± 0.06 0.53 ± 0.14*
The amount of α-, β- or γ -ENaC in biotinylated surface proteins of HEK-293 cells transiently transfected with WT or mutant ENaC constructs was quantified by Western blot experiments
according to β-tubulin. All samples were set in relation to the α- (see Wild Type), β- or γ - (data not shown; compare Shabbir et al., 2015) ENaC surface expression of WT control,
respectively. For mutant ENaC mean values ± SEM of 3–5 independent biological replicates are given (WT: n = 26). All controls were compared to WT control,
†††
p < 0.001. After
treatment with solnatide and AP318 at indicated time points significant difference was calculated compared to the control values of the respectively same mutation, *p < 0.05, **p <
0.01, ***p < 0.001.
of these proteins may be viewed as functional modules. In the
case of α-ENaC, the finger domain has been associated with
activation of ENaC through protease cleavage (Kashlan et al.,
2010, 2011), Na+ sensitivity and Na+ self-inhibition (Kashlan
et al., 2010), as well as the modulation of channel activity in
response to shear stress (Shi et al., 2012).
Both mutants, αS243P and αS243fs, showed a marked
decrease in amiloride-sensitive current, which was even more
pronounced in the case of the point mutation. Similar to the
αS562P mutant (Boiko et al., 2015) discussed above, a change of
the polar amino acid serine at position 243 to the heterocyclic,
non-polar proline would introduce rigidity into the protein
backbone which might in turn result in a deleterious change
to the tertiary structure of the protein, thereby interfering
with function. In addition, the mutants prominently differed
regarding membrane expression. Whilst membrane abundance
of αS243P was dramatically reduced, the frameshift mutant was
significantly more highly expressed in the membrane compared
to WT ENaC. Residue S243 is located fifty or so amino acids
further along the polypeptide chain from the furin cleavage sites
flanking the inhibitory tract between R178 and R204, the excision
of which is required for full ENaC activity due to suppression of
Na+ self-inhibition (Kleyman et al., 2009; Kashlan et al., 2010,
2012; Hanukoglu and Hanukoglu, 2016), so it is unlikely that
the mutated residue would interfere with the cleavage reaction.
However, in the homology model of mouse α-ENaC, S270, the
equivalent residue to S243 in human α-ENaC lies in proximity
with the central portion of the inhibitory peptide (Kashlan
et al., 2011). It is likely that the marked decrease in amiloride-
sensitive current observed with the S243P mutant is due to
this mutation interfering with release of the cleaved peptide
from the channel surface, thus favoring self-inhibition. The
substituted proline residue introduces rigidity into the protein
backbone and the resulting conformational inflexibility could
prevent release of the inhibitory peptide. Regarding the S243fs
mutation a truncated protein of 247 residues with a bulky C-
terminus (S242SGWMR-COOH) is produced, which may not be
correctly folded, either for furin cleavage or for heterooligomeric
assembly. These results are consistent with several studies in
which systematic mutagenesis of residues in this region of α-
ENaC has demonstrated their involvement in Na+ self-inhibition
(Kashlan et al., 2010, 2011). Moreover, the S243fs mutant lacks
the “PPxY” and “YXX8” motifs located in the intracellular
carboxyl terminal region and required for ubiquitination and
endocytosis, in the absence of which subunits accumulate at the
cell surface (Wiemuth et al., 2007; Bobby et al., 2013). This would
explain the significantly higher expression in the membrane of
the frameshift mutant compared both to WT ENaC as well as to
the S243P point mutant.
The extracellular loop of all ENaC subunits contains 16
conserved Cys residues that can be grouped into two cysteine-
rich domains (CRDs). One pair of cysteines, (C229 and C236 in
human α-ENaC) in the finger domain is not present in ASIC1 and
so the disposition of these cysteines is so far unclear (Sheng et al.,
2000). Chemical cross-linking to the finger domain cysteines of
both the α- and γ-subunits has revealed that they lie in close
proximity to the finger-thumb domain interface of the respective
subunits; furthermore this cross-linking affected ENaC currents,
suggesting mechanical linkage between this peripheral site and
the channel gate (Blobner and Kashlan, 2016).
Both whole-cell current and subunit membrane abundance,
were significantly increased by solnatide and AP318. The TM2
domain of the glycosylated α-subunit has recently been identified
as a crucial target for binding of TIP peptides (Czikora et al.,
2014; Shabbir et al., 2015). So frameshift mutations which
precede the C-terminal domain will disrupt this condition for
drug binding, as is the case for the frameshift at position 243
which results in a premature stop codon only four amino
acids after the affected serine residue, and hence a truncated
polypeptide chain. Moreover, we have previously shown that
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solnatide (Shabbir et al., 2013) and AP318 (unpublished data)
can induce an increase in amiloride-sensitive Na+ current
with βγ-ENaC, whereas the membrane abundance of β- and
γ-ENaC stays unchanged (Shabbir et al., 2015). Interestingly
the amiloride-sensitive control current and solnatide-induced
current of αS243fs co-expressed with βγ-ENaC were significantly
higher than βγ-ENaC alone (compare with Shabbir et al., 2013),
indicating that even the truncated α-subunit retains some kind
of functionality or at least stabilizes the channel complex. This
implies that the TIP peptides are able to activate ENaC via an
additional mechanism, although this mechanism appears to be of
secondary importance under normal conditions.
Effect of TIP Peptides on Non-TM Mutants
Both peptides, solnatide and AP318, increased reduced
amiloride-sensitive current in αC133Y, αG327C and βG37S
mutants to control levels of WT ENaC or even higher. αC133Y
occurs in the first cysteine rich domain of ENaC (Firsov et al.,
1998; Bonny et al., 1999, 2002; Bonny and Hummler, 2000).
Mutations in this region might influence the formation of
disulphide bonds and consequently tertiary structure of the
channel protein, however, obviously without preventing binding
of the TIP peptides to the postulated binding sites. Edelheit
et al. (2011) showed that mutation of specific conserved charged
residues to alanine may affect the surface density of α-ENaC,
and that there was a high degree of correlation between ENaC
Na+ conductance activity and the surface density of ENaC. We
could not find this correlation for αC133Y. On the contrary, for
αC133Y we found significantly higher membrane expression.
So, there was a clear discrepancy between functionality and
membrane abundance for this mutant. The αC133Y mutation
would disrupt the disulfide bridge between C133 and C305
(Sheng et al., 2007) located on the neighboring strand in the
β-ball (β5 according to the homology model of mouse α-ENaC)
(Kashlan and Kleyman, 2011), and therefore important for the
structural integrity of this domain which lies at the core of the
subunit. It is likely that this mutation causes serious disruption
to the conformation of the subunit.
In our setting, current reduction in the αG327C mutant
(Edelheit et al., 2005) is consistent with the data published
by Hanukoglu et al. (2008). These authors suggested that the
reason for reduced ENaC activity in the mutant could be due
to the larger side chain of cysteine compared to the more
flexible glycine which would weaken or interfere with subunit
interaction (Hanukoglu et al., 2008). Furthermore, the cysteine
of the mutant could potentially participate in formation of non-
native disulphide bonds during the folding process resulting in
a misfolded subunit. According to alignment with the Kashlan
model of α-mENaC (Kashlan and Kleyman, 2011), the mutation
αG327C is located on the surface of the α-subunit at the boundary
between the β-ball and palm domains and near the vertical axis
of rotational symmetry down the center of the trimer. Edelheit
et al. (2014) suggested it is likely that residues at this location
are involved in conformational changes that lead to channel
constriction and the Na+ self-inhibition response upon Na+
ion flooding. The αG327C mutant, of all mutants described
in this work, is the one which showed the largest response to
activation of Na+ current by both peptides—particularly so to
AP318. Considering the putative location of this mutation at the
interface of the three subunits, this observation lends weight to
the argument that TIP peptides exert their effect by interfering
with intersubunit conformational changes.
The mutant βG37S occurs in the HGmotif of ENaC channels.
ENaC carrying mutations in the HG motif show altered gating
properties characterized by abnormally long closures and short
channel openings corresponding to a loss-of-function mutation
(Chang et al., 1996; Gründer et al., 1997). Reduced whole-
cell current was accompanied by slightly lower membrane
expression, but access of the TIP peptides to the binding site in
the α-subunit is apparently not inhibited by the mutation in the
N-terminal domain of the β-subunit.
CONCLUSION
There are different proven or speculative reasons for reduced
functionality of the ion channel, resulting in altered channel
pore formation and gating as well as protein expression in
the membrane. However, whatever mechanism leads to loss-of-
function of the studied ENaC mutations, the synthetic peptides
solnatide and AP318 could restore ENaC function of conserved
PHA1B mutants to at least current levels of WT ENaC. This
implies that the TIP domain activates ENaC by some mechanism
which remains intact even in the presence of various mutations
occurring in different subunits, because binding to the putative
binding site in the carboxyl terminal domain of the glycosylated
α-subunit apparently remains basically unaffected in all tested
point mutations or was compensated in frameshift mutations
via a moderate activation of αβ- and βγ-ENaC, respectively.
Collier et al. (2014) showed that residues located in the
wrist region (which lies above the transmembrane domain) at
equivalent positions at the interface of the thumb and palm
domains in α-, β-, and γ-subunits, form intersubunit interfaces
between which conformational changes are critical to ENaC
gating. Cross-linking of these residues alters ENaC activity. Long
cross-linkers increase ENaC current, whereas short cross-linkers
reduce ENaC open probability. The current activating effect
of TIP peptides in all PHA1B mutants could be explained by
their interfering with conformational changes between subunit
interfaces in the wrist region such as to increase intersubunit
distance and thereby channel open probability. In any case, as
therapy of PHA1B is only symptomatic so far, the TIP peptides
solnatide and AP318, which directly target ENaC, are promising
candidates for the treatment of the channelopathy caused disease
PHA1B.
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